Associate Professor of Oncology, Associate Professor of Medicine, Johns Hopkins University School of Medicine
Oncology
Dr. Yvette L. Kasamon, MD
|
|
Give Review
Dr. Yvette L. Kasamon is an expert in the field of Oncology. She researched medicine at University of Pittsburgh School of Medicine. Yvette L. Kasamon, MD is a published MD. She published 44 publications, including: 'Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by ...' Yvette Kasamon accepts Medicare.
Publications
- Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome.
- Risk-stratified outcomes of nonmyeloablative, HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.
- Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/Leukemia.
- Post-transplantation cyclophosphamide as single-agent GVHD prophylaxis after myeloablative conditioning and HLA-matched allografting for Acute leukemias and myelodyspl...
- Induction of high-titer IgG antibodies against multiple Leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy.
- Sustained remission and reversal of end-organ dysfunction in a patient with anaplastic Myeloma.
- Radiobiologic Optimization of Combination Radiopharmaceutical Therapy Applied to Myeloablative Treatment of Non-Hodgkin Lymphoma.
- Absence of Post-Transplantation Lymphoproliferative Disorder after Allogeneic Blood or Marrow Transplantation Using Post-Transplantation Cyclophosphamide as Graft-vers...
- Partially Mismatched Transplantation and Human Leukocyte Antigen Donor-Specific Antibodies.
- Outcomes of Related Donor HLA-Identical or HLA-Haploidentical Allogeneic Blood or Marrow Transplantation for Peripheral T Cell Lymphoma.
- Human leukocyte antigen-haploidentical hematopoietic stem cell transplant for a patient with histiocytic sarcoma.
- EBV-associated Lymphoma and chronic inflammatory demyelinating polyneuropathy in an adult without overt immunodeficiency.
- MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell Carcinoma.
- FDG PET and high-dose therapy for aggressive Lymphomas: toward a risk-adapted strategy.
- Treatment advances in adult Burkitt lymphoma and Leukemia.
- Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell Lymphoma.
- High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central Nervous system involvement.
- AIDS-related primary central Nervous system lymphoma.
- Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic Leukemia.
- Management of symptomatic, untreated chronic lymphocytic Leukemia.
- Integrating PET and PET/CT into the risk-adapted therapy of Lymphoma.
- Blood or marrow transplantation for mantle cell Lymphoma.
- Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk Lymphoma.
- Immunotherapies for Hodgkin''s Lymphoma.
- FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's Lymphoma.
- Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin Lymphoma based on midtreatment FDG-PET scanning.
- Circulating clonotypic B cells in classic Hodgkin Lymphoma.
- K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid Leukemia patients with residual disease on imatinib mesylate.
- Extended follow-up of autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide (4-HC) purging for indolent or transformed non-Hodgkin Lymphomas.
- Prognostication and Risk-Adapted Therapy of Hodgkin's Lymphoma Using Positron Emission Tomography.
- Treatment of hematological Malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamide.
- Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide.
- Autologous human monocyte-derived dendritic cells genetically modified to express Melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by ...
- Mean genes and the biology of aggression: a critical review of recent animal and human research.
- gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cells.
- High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell Lymphomas.
- Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic Leukemia.
- High-dose cyclophosphamide as single-agent, short-course prophylaxis of Graft-versus-host disease.
- Self-medication and intractable cough.
- From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.
- Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell Lymphoma.
- Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder.
- Salvage transplantation for alloGraft failure using fludarabine and alemtuzumab as conditioning regimen.
Schools
University of Pittsburgh Main Campus
Brigham and Women39s Hospital
Procedures Preformed
- Bone Marrow Transplant
- HPC Transplantation (Stem Cell Transplant)
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Johns Hopkins University -
Brigham and Women's Hospital -
University of Pittsburgh School of Medicine
Hospital
-
Johns Hopkins Hospital
Drug Facts
| NPI NUMBER | 1578510756 | |
| NPPES Provider LastName | KASAMON | |
| NPPES Provider FirstName | YVETTE | |
| NPPES Provider ZIPCode | 212870005 | |
| NPPES Provider State | MD | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 75.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1578510756 |
| Last Name Of The Provider | KASAMON |
| First Name Of The Provider | YVETTE |
| View All |
Similar Doctors
|
|
Dr. Lode J. Swinnen, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Mohamad E. Allaf, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Robert B. Donegan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hetty E. Carraway, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Evan J. Lipson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maria Baer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elizabeth M. Jaffee, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ephraim J. Fuchs, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. David D. Sidransky, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kenneth J. Pienta, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Michael A. Carducci, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Fang Yin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark J. Levis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. B D. Smith Jr., MD |
|
|
Dr. William B. Dalton, MD |
|
|
Adrian G. Murphy, MB CHB |